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ABSTRACT 
ANCA associated vasculitis (AAV) is a heterogeneous group of diseases characterised by 
sterile pauci-immune systemic small vessel inflammation and closely associated with the 
presence of anti-neutrophil cytoplasmatic antibodies (ANCA). Although AAV can affect any 
organ, the kidney, skin, lungs and upper and lower airways are most commonly involved. In 
some patients there is granuloma formation and in some asthma and eosinophilia, and based 
on this patients can be further classified as microscopic polyangiitis (MPA) (no granuloma), 
granulomatosis with polyangiitis (GPA) or eosinophil granulomatosis with polyangiitis 
(EGPA). Induction treatment of AAV consists of a cytotoxic agent in combination with 
glucocorticoids and is usually effective, although relapse, infections and drug toxicity remain 
a problem. The aim of this thesis was to investigate the role of novel proinflammatory 
molecules in the pathogenesis of AAV and as markers of disease. We also wanted to 
investigate the outcome of new therapies. 
In paper I we investigated the pro-inflammatory mediator high-mobility group box-1 protein 
(HMGB1) in patients with active AAV and in remission. Elevated levels of circulating 
HMGB1 were found in active disease compared to inactive disease. We found increased 
expression of HMGB1 in renal tissue of patients with active renal AAV compared to inactive 
AAV, indicating a role for HMGB1 in AAV.  
In paper II we carried out a long time follow-up on patients treated with rituximab as a 
second line treatment in patients with refractory or relapsing disease. We found that a high 
proportion of patients achieved remission but there were several adverse events including two 
cases of hepatitis B reactivation. Patients with a negative conventional ANCA but positive 
capture ANCA seemed to be at risk of relapse after rituximab treatment. 
In paper III macrophage inhibitory factor and thyroid hormones were investigated 
prospectively in 30 patients with active AAV. We found that levels of MIF were elevated in 
active disease compared to remission and that MIF levels correlated with disease activity. 
There were thyroid hormone alterations with lower triiodothyronine in active disease, similar 
to what has previously been described in critically ill patients. In addition there was an 
indication of an interaction between MIF and thyroxine similar to what has previously been 
described in sepsis. 
In paper IV we investigated pentraxin – 3 (PTX3) and soluable Tumor necrosis factor-like 
weak inducer of apoptosis (sTWEAK) in 40 patients with active AAV and found that PTX3 
was elevated in active disease compared to remission and correlated with disease severity. 
sTWEAK levels in active disease did not significantly change compared to remission, but 
seemed to vary with disease phenotype. Patients with high sTWEAK and low PTX3 were 
less likely to achieve remission. 
In conclusion several proinflammatory molecules may be implicated in the pathogenesis and 
exacerbation of AAV and are possible targets of therapy. There seems to be thyroid hormone 
alterations in active AAV and there may be an interaction between MIF and thyroxine in 
AAV. PTX3 may be a useful marker of disease. Rituximab may be a useful treatment in 
refractory or relapsing disease but it is important to assess hepatitis status and adverse events 
are a concern. 
  
  
LIST OF SCIENTIFIC PAPERS 
This thesis is based on the following papers, which will be referred to in the text by their 
Roman numerals. 
I. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, 
Palmblad K and Gunnarsson I. ”High-mobility group box-1 protein 
(HMGB1) is increased in antineutrophilic cytoplasmatic antibody 
(ANCA)-associated vasculitis with renal manifestations” Mol Med. 
2011 17: 29-35. 
 
II. Wendt M, Gunnarsson I, Bratt J and Bruchfeld A.”Rituximab in 
relapsing or refractory ANCA-associated vasculitis: a case series of 
16 patients” Scand J Rheumatol. 2012 41:116-9.  
 
III. Wendt M, Börjesson O, Avik A, Bratt J, Anderstam B, Qureshi AR, 
Miller EJ, Gunnarsson I and Bruchfeld A. ”Macrophage Migration 
Inhibitory Factor (MIF) and Thyroid Hormone Alterations in 
Antineutrophil Cytoplasmatic Antibody (ANCA)-Associated Vasculitis 
(AAV)” Mol Med. 2013 20:109-14. 
 
IV. M Wendt, O Börjesson, A Avik, J Bratt, AR Qureshi, I Gunnarsson 
and A Bruchfeld. PTX3 and soluble TWEAK levels in active ANCA 
associated vasculitis (AAV) patients undergoing treatment – 
correlation to disease activity and relapse” Manuscript 
 
 
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Overview of the immune system .......................................................................... 1 
1.1.1 Innate immunity ....................................................................................... 1 
1.1.2 Inflammation ............................................................................................ 1 
1.1.3 Adaptive immunity .................................................................................. 1 
1.1.4 Autoimmunity .......................................................................................... 1 
1.2 Systemic vasculitis ............................................................................................... 2 
1.3 Anti-neutrophil cytoplasmic antibodies (ANCA) ................................................ 3 
1.3.1 ANCA testing .......................................................................................... 3 
1.3.2 The significance of ANCA ...................................................................... 4 
1.3.3 The origin of ANCA ................................................................................ 4 
1.4 ANCA associated Vasculitis (AAV) ................................................................... 4 
1.4.1 Clinical presentation and disease progression ......................................... 5 
1.4.2 Epidemiology ........................................................................................... 5 
1.4.3 Diagnosis .................................................................................................. 6 
1.4.4 Pathogenesis ............................................................................................. 6 
1.4.5 Scoring disease activity and damage ..................................................... 10 
1.5 Treatment of AAV ............................................................................................. 11 
1.5.1 Induction treatment ................................................................................ 12 
1.5.2 Maintenance treatment ........................................................................... 13 
1.6 Monitoring AAV ................................................................................................ 14 
1.7 Objectives of the studies ..................................................................................... 14 
2 Materials and methods .................................................................................................. 17 
2.1 Patients ................................................................................................................ 17 
2.1.1 The VASKA cohort ............................................................................... 17 
2.1.2 Study patients ......................................................................................... 17 
2.1.3 Controls .................................................................................................. 18 
2.2 Assessment of disease activity and damage ....................................................... 19 
2.3 Treatment ............................................................................................................ 19 
2.4 Laboratory measurement .................................................................................... 19 
2.4.1 Routine laboratory parameters .............................................................. 19 
2.4.2 ANCA .................................................................................................... 19 
2.4.3 Analysis of HMGB1 .............................................................................. 20 
2.4.4 Analysis of MIF, PTX3 and sTWEAK ................................................. 20 
2.5 Histological Assessment ..................................................................................... 20 
2.5 Statistics .............................................................................................................. 20 
3 Results and discussion .................................................................................................. 23 
3.1 Paper I ................................................................................................................. 23 
3.2 Paper II ................................................................................................................ 25 
3.3 Paper III .............................................................................................................. 26 
3.4 Paper IV .............................................................................................................. 27 
  
4 General Discussion ........................................................................................................ 30 
4.1 Methodological considerations ........................................................................... 30 
4.1.1 Patient cohort ......................................................................................... 30 
4.1.2 Treatment and response ......................................................................... 30 
4.1.3 Strengths and limitations ........................................................................ 31 
4.2 Findings and implications ................................................................................... 32 
4.2.1 Persistently elevated levels of proinflammatory molecules after 
treatment ................................................................................................. 32 
4.2.2 The role of rituximab as rescue treatment ............................................. 32 
4.2.3 Biomarkers ............................................................................................. 33 
4.2.4 Outcome and prognosis ......................................................................... 34 
4.2.5 Future perspectives ................................................................................ 34 
5 Conclusions ................................................................................................................... 36 
6 Svensk sammanfattning ................................................................................................ 37 
7 Acknowledgements ....................................................................................................... 39 
8 References ..................................................................................................................... 41 
 
  
LIST OF ABBREVIATIONS 
AAV 
ACR 
ANCA Associated Vasculitis 
American College of Rheumatology 
ANCA 
AZA                                              
Anti-neutrophil cytoplasmic antibodies 
Azathioprine 
BVAS 
C 
CKD 
CMV 
Birmingham Vasculitis Activity Score 
Complement component 
Chronic kidney disease 
Cytomegalovirus 
CRP 
CSS 
CYC 
DAPI 
eGFR 
EGPA 
ELISA 
EULAR 
EUVAS 
Fn 14 
GC 
GPA 
HbcAg 
HbeAg 
HbsAg 
HLA 
HMGB1 
IG 
IgG 
IL 
i.v. 
LPS 
C-reactive protein 
Churg-Strauss syndrome 
Cyclophosphamide 
4',6-diamidino-2-phenylindole 
Estimated glomerular filtration rate 
Eosinophilic granulomatosis with polyangiitis  
Enzyme-linked immunosorbent assay 
The European league against rheumatism 
European vasculitis study group 
Fibroblast growth factor-inducible molecule 14 
Glucocorticoids 
Granulomatosis with polyangiitis (Wegener's granulomatosis) 
Hepatitis B core antigen 
Hepatitis B e antigen 
Hepatitis B Surface antigen 
Human Leukocyte antigen 
High mobility group box 1 
Immunoglobulin 
Immunoglobulin G 
Interleukin 
Intravenously 
Lipopolysaccharide 
  
MCP-1 
MDRD 
MIF 
MMF 
MPA 
MPO 
MTX 
NET 
NF-κβ 
PAMP 
PRR 
PR3 
PSGL-1 
PTX3 
RA 
RTX 
SLE 
T3 
T4 
T-cells 
TNF 
TSH 
TWEAK 
VDI 
 
 
Monocyte chemoattractant protein – 1 
Modification of diet in renal disease 
Macrophage migration inhibitory factor 
Mycophenolate Mofetil 
Microscopic Polyangiitis 
Myeloperoxidase 
Methotrexate 
Neutrophil Extracellular Trap 
Nuclear factor kappa-light-chain-enhancer of activated B cells 
Pathogen-associated molecular patterns 
Pattern recognition receptors 
Protinase 3 
P-selectin glycoprotein ligand-1 
Pentraxin – 3 
Rheumatoid arthritis 
Rituximab 
Systemic lupus erythematosus 
Triiodothyronine 
Thyroxine 
Thymic-derived lymphocytes 
Tumour necrosis factor 
Thyroid-stimulating hormone 
Tumor necrosis factor-like weak inducer of apoptosis 
Vasculitis Damage Index 
 

  1 
1 INTRODUCTION 
1.1 OVERVIEW OF THE IMMUNE SYSTEM 
The major function of the immune system is to protect the body from invading 
microorganisms. 
1.1.1 Innate immunity 
The innate immune system reacts to invading pathogens in a generic way and carries no long 
lasting memory (immunity) against a microorganism. The innate immune system recognises 
molecular patterns found in a broad group of microorganisms (pathogen-associated molecular 
patterns, PAMPSs) by pattern recognition receptors (PRR). The best-characterised PRRs are 
a group of transmembrane proteins called Toll-like receptors. They recognise extracellular 
PAMPs and trigger the synthesis and secretion of cytokines necessary for the immune 
response. 
Cells involved in innate immunity include macrophages, neutrophils, dendritic cells, 
eosinophils and natural killer cells. Innate immunity also consists of biological and chemical 
barriers, inflammatory mediators such as cytokines and the complement system. 
1.1.2 Inflammation 
Inflammation is a complex biological response of vascular tissues to pathogens, injured cells 
or irritants amongst others. The classic signs are pain, heat, redness, swelling and loss of 
function. On a cellular and molecular level, cells in the innate immune system are activated 
when they recognise PAMPs, and releases inflammatory mediators such as the cytokines 
TNF, IL-1 and IL-10. Neutrophils are recruited to the injured area by the process of 
chemotaxis and the complement system is activated. Inflammatory mediators have short half-
lives, hence the acute inflammatory response needs constant stimulation to be sustained. 
1.1.3 Adaptive immunity 
Adaptive immunity is characterised by an immunological memory, high specificity and a 
stronger reaction to subsequent exposures to the same antigen. Adaptive immune responses 
are dependent on antigen-presenting cells displaying antigens. Probably the most important 
antigen-presenting cells are the dendritic cells (DC), abundantly situated in tissue exposed to 
potential pathogens such as skin, lungs, intestine and kidneys. DC are an important link 
between innate and adaptive immunity. Basically adaptive immune reactions comprise 
humoral immunity, which is mediated by B-cells and antibodies, and cellular-mediated 
immunity, mainly mediated by T-cells. 
1.1.4 Autoimmunity 
A fundamental property of the immune system is to discriminate between self and non-self. 
Lymphocytes with auto reactivity are inactivated or eliminated thus maintaining 
immunological tolerance. Failure to do so will result in an immune response to the body’s 
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own cells and tissues. A low level of autoimmunity can be found in healthy individuals and 
may in fact be beneficial but a specific and effective immune reaction against self-antigens 
will result in injury and autoimmune disease. The development of autoimmunity and 
autoimmune disease is generally seen as a combination of genetic, hormonal and 
environmental factors. Genes implicated in autoimmunity include genes related to 
immunoglobulin’s, T-cell receptors and the human leukocyte antigen (HLA). Most 
autoimmune diseases predominantly affect women. Drugs, microorganisms and cigarette 
smoke are environmental factors linked to autoimmunity [1]. 
1.2 SYSTEMIC VASCULITIS 
The systemic vasculitides are a heterogeneous group of diseases characterised by 
inflammation of the blood vessel wall leading to narrowing, obstruction or other destruction 
of the vessel with subsequent infarction and tissue damage. Both arteries and veins are 
affected. Broadly speaking, the underlying cause of disease can be divided into infectious and 
non-infectious. Infectious vasculitis is caused by an invading pathogen affecting the vessel 
wall, as for instance in the case of syphilitic aortitis, whereas non-infectious vasculitis is not 
caused by a direct invasion and proliferation in the vessel wall by a pathogen. The non-
infectious vasculitides are further categorised primarily according to the size of the affected 
vessels [2]. 
 
Figure 1. Distribution of vessel involvement by the different vasculidities. Categorisation is made 
according to the vessel predominantly affected (i.e. large vessel vasculitis, medium vessel vasculitis 
and small vessel vasculitis.) A single disease entity can affect many types of vessels. Reproduced from 
Jennette et al [2] with permission from the publisher. 
 
  3 
1.3 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) 
Anti-neutrophil cytoplasmic antibodies are a group of autoantibodies directed against 
antigens in the cytoplasm of neutrophils. Although found in a number of autoimmune 
conditions, ANCA is particularly associated with a group of systemic small vessel 
vasculitides, the so-called ANCA associated vasculitides (AAV). Typically ANCA is of IgG 
type and directed against proteinase 3 (PR3) or myeloperoxidase (MPO) however there are 
several other known ANCA antigens of unclear significance [3, 4]. 
1.3.1 ANCA testing 
ANCA can be detected by immunofluorescence (IF), where two typical patterns can be seen: 
cytoplasmic ANCA (c-ANCA) and perinuclear ANCA (p-ANCA). The typical c-ANCA 
antigen is PR3 and the typical c-ANCA antigen is MPO, but there are several atypical ANCA 
antigens that can give rise to p- and c-ANCA patterns. Usually an Enzyme-Linked 
ImmunoSorbent Assay (ELISA) is carried out after a positive IF, testing for PR3 and MPO. 
Testing for ANCA with ELISA is traditionally done with a direct ELISA, where the antigen 
binds directly to the plastic in the wells. A variant of the solid phase ELISA is the bead-based 
multiplex assay in which capture antigens are bound to colour-coded beads in suspension that 
are then analysed using flow cytometry. With this method one can simultaneously detect 
multiple autoantibodies [5, 6]. Newer generations of ELISAs use a capture molecule, usually 
a monoclonal antibody, to bind the antigen. Theoretically, capture ANCA will further purify 
the antigen and preserve the three-dimensional structure leading to increased sensitivity and 
specificity [6, 7]. 
 
Figure 2. Appearance of cytoplasmic indirect immunofluorescence pattern (C-ANCA, Figure 1(a)) 
and perinuclear (P-ANCA, Figure 1(b)) on ethanol-fixed human neutrophil cells. Reproduced from 
Schulte-Pelkum et al [8]. 
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1.3.2 The significance of ANCA 
In the clinic, ANCA testing is primary used for diagnosing vasculitis. The presence of ANCA 
is not pathognomonic of AAV however and a negative ANCA test does not exclude AAV. 
The result of an ANCA test needs to be correlated with clinical signs and symptoms [9]. A 
reappearance of ANCA in a known AAV patient may indicate a relapse but several patients 
have a positive ANCA without any detectable disease activity [10, 11].  
Although still controversial, most current theories attribute ANCA a causal role in the 
development of AAV [12]. It is believed however, that only some of the epitopes recognised 
by ANCA are pathogenic, thus explaining why there is no clear link between ANCA levels 
and disease activity [13-15]. 
1.3.3 The origin of ANCA 
Low titres of non-pathogenic ANCA can be found in healthy people [16] but why some 
patients develop high titres and disease remains elusive. A genome-wide association study 
suggests a genetic contribution to the development of ANCA in ANCA associated vasculitis 
with different HLA specificities correlating to the development of MPO ANCA vasculitis and 
PR3 ANCA vasculitis. This association was stronger than with the clinical phenotype. In 
addition genes coding for α1-antitrypsin and PR3 ANCA were associated with PR3 ANCA 
vasculitis [17].  
Environmental factors are also probably important and microorganisms such as 
Staphylococcus aureus [18] and Ross River virus [19] has been implicated in the induction of 
ANCA associated disease. Furthermore, antithyroid drugs such as propylthiouracil can induce 
high ANCA titres and sometimes AAV [20] and exposure to silica [21] are related to the 
development of AAV. 
 
1.4 ANCA ASSOCIATED VASCULITIS (AAV) 
The ANCA associated vasculidities consists of three diseases: Microscopic polyangiitis 
(MPA), Granulomatosis with polyangiitis (GPA, formerly known as Wegener's 
granulomatosis) and Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known 
as Churg-Strauss syndrome). They have a similar clinical presentation, affecting small- to 
medium-sized vessels and are associated with the presence of ANCA. Immunopathologically, 
AAV has an absence of immunoglobulin dispositions in injured vessels (pauci-immune 
vasculitis), separating AAV from immune-complex-mediated small vessel vasculitis. AAV 
can involve virtually any organ but lungs, kidneys, skin and peripheral nerves are the most 
commonly affected organs. In addition, some variants of AAV (GPA and EGPA) have 
extravascular necrotising granulomatous inflammation (granuloma) most commonly affecting 
upper and lower airways [2]. 
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1.4.1 Clinical presentation and disease progression 
AAV is very heterogeneous in its clinical presentation but an archetypical patient is a man or 
a woman in their 5th to 7th decade of life [22] with upper and lower airway involvement and 
rapidly progressive renal failure. Other common presentations are limited granulomatous 
disease without signs of systemic angiitis, and organ limited vasculitis, most commonly renal 
limited vasculitis. AAV can also affect younger individuals and even children. 
The natural history of AAV is grim and before causal treatment was available mean survival 
was only five months and one year mortality was 82% [23]. After the introduction of 
cyclophosphamide (CYC) in the 1970s outcome improved drastically with survival rates of 
80% at follow up after eight years [24]. With modern treatment, the disease has a typical 
remitting-relapsing course although some patients enjoy lifelong remission. With 
conventional immunosuppression, 38% of ANCA patients included in four different 
European vasculitis study group (EUVAS) trials relapsed within five years and 25% died 
[25]. Some patients demonstrate residual disease activity after treatment and some patients 
are refractory to standard treatment altogether. 
Risk factors for relapse in AAV patients include positive PR3 ANCA [26], upper and lower 
airway involvement and diagnosis of GPA[27]. Recent findings suggest that ANCA titres 
correlate more strongly with relapse in patients with renal vasculitis [28]. 
1.4.2 Epidemiology 
In a study from southern Sweden, the incidence of AAV was about 21 new cases per 
million/year. About half of the cases were GPA and half MPA. EGPA was a very rare disease 
with an incidence of about one case per million/year. The male to female ratio was 1:1 and 
the median age 67.6 years at diagnosis. The one- and five-year survival rates were 87.8% and 
71.6% for all patients with MPA carrying a worse prognosis due to higher age and lower 
glomerular filtration rate (GFR). Mortality was 2.77 times higher than in the general 
population [29]. Similar incidence of AAV has been reported from England whereas lower 
incidence has been reported from Germany [22, 30]. From reported data it seems as if the 
incidence of these diseases is increasing, this may be due to increased recognition of AAV 
following the introduction of ANCA testing. Furthermore, methodological differences such 
as whether AAV is defined by ACR criteria or Chapel hill consensus criteria or cases are 
captured by international classification of disease codes (ICD) may be of relevance when 
comparing different incidence rates [22]. 
Relatives of AAV patients have only a slightly increased risk of acquiring AAV [31]. 
Generally AAV is rarely seen in concurrence with other autoimmune diseases with the 
exception of thyroid disease [32]. 
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1.4.3 Diagnosis 
The diagnosis of AAV is based on clinical presentation, histopathology and ANCA testing. If 
there is pauci-immune small vessel vasculitis present without granuloma or asthma the 
patient is categorised as MPA, if there is granuloma but no asthma the patient is categorised 
aGPA and if there is granuloma, asthma and eosinophilia the patient is categorised as EGPA 
[2, 33] (figure 3). Patients can also be classified according to ANCA specificity (MPO or 
PR3 positive) [12]. MPA patients most commonly display MPO ANCA and GPA patients 
display PR3 ANCA although there is a substantial overlap. If ANCA is present in EGPA 
patients it is usually MPO ANCA [34].  
 
 
Figure 3. Categorisation algorithm of AAV. 
 
The American College of Rheumatology (ACR) has issued classification criteria for GPA 
[35] and EGPA [36]. No ACR classification criteria exist for MPA. 
1.4.4 Pathogenesis 
The pathogenesis of AAV is largely unknown, especially the early stages of the disease. In 
current theories, it is suggested that neutrophils and monocytes in the circulation are primed 
by inflammatory stimuli and as a result display ANCA antigens on or near the cell surface. 
ANCA then interacts with these antigens leading to neutrophil activation and thereby 
initiating the vascular inflammation. In a similar fashion, granuloma formation is due to 
primed extravascular neutrophils interacting with interstitial ANCA, causing necrotising 
extravascular inflammation as the first stage in granuloma formation [12]. 
1.4.4.1 ANCA 
There are several observations and findings that implicate ANCA in the pathogenesis of 
AAV. In the clinic, a strong association between ANCA and disease (MPA >90%, GPA >90 
%, EGPA >40 %) can be observed, as well as a correlation between ANCA titre and disease 
Pauci-immune vasculitis 
Systemic vasculitis 
without 
granuloma or astma 
MPA 
Systemic vasculitis with 
granuloma but without 
astma 
GPA 
Systemic vasculitis with 
granuloma, astma and 
eusinophilia 
EPGA 
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activity (albeit only partial correlation). Also, these diseases response well to B-cell depletion 
and plasmapheresis indicating that removal of autoantibodies resolves clinical disease [12]. 
In pathomechanistic studies of AAV, ANCA activate neutrophils and induce them to 
degranulate and produce oxygen radicals in vitro [37]. In rodent models of ANCA associated 
disease, anti MPO antibodies induce necrotising and crescentic glomerulonephritis either by 
direct injection, injecting splenocytes containing anti-MPO cells into immunodeficient mice 
or transplanting bone marrow that contains MPO positive myeloid cells into MPO knock-out 
mice [38, 39]. In some animals, systemic necrotising small vessel vasculitis and granuloma 
formation can be seen. These lesions closely resemble AAV in humans. Anti MPO IgG had 
this effect even in knock-out mice lacking functional T and B cells [40]. Although this 
strongly suggests the pathogenic role of ANCA, it should be pointed out that similar evidence 
does not exist for PR3 ANCA. 
1.4.4.2 Complement 
Although described as pauci-immune (no or minimal presence of immunoglobulins and/or 
complement), when closely examining renal biopsies from patients with active renal AAV, 
complement deposition is often found [41]. Furthermore, in patients with AAV plasma levels 
of the alternative complement pathway constituents: C3a, C5a and soluble C5b-C9 have been 
reported as being higher in active disease than in remission, whereas no difference could be 
seen for the classical pathway constituent C4d [42]. In mice models of AAV, blocking C5 
either by knockout C5-/- or by a C5 inhibiting monoclonal antibody prevented the 
development of pauci immune glomerulonephritis that developed in control animals [43, 44]. 
This supports the view that complement, acting through the alternate pathway, mediates the 
necrotising vasculitis found in AAV. C5a is a strong neutrophil activator and recruits 
additional neutrophils through chemotaxis. These neutrophils exposed to C5a can activate the 
alternate pathway creating more C5a, thus creating a positive feedback loop [45].  
1.4.4.3 Neutrophils and monocytes 
A number of observations put the neutrophil at the centre of AAV pathogenesis. Obviously, 
neutrophils contain the antigen for ANCA and neutrophils are found in significant amounts in 
early glomerular and granulomatous lesions. The fact that AAV lesions are pauci-immune 
also suggests a direct cellular action pathogenesis [12]. There is strong evidence that 
neutrophils are recruited by chemotaxis to sites of vascular inflammation and that ANCA 
induces a respiratory burst and degranulation. In this setting neutrophils also undergo netting, 
a process in which chromatin fibres, so called neutrophil extracellular traps (NETs), are 
released. NETs display the MPO and PR3 antigens, suggesting that NET formation and 
deposition can trigger vasculitis and promote its exacerbation [46]. Apart from ANCA, many 
other events can induce and sustain neutrophil netting, for instance bacterial infections with 
Staphylococcus aureus [47] and the antithyroid drug propylthiouracil [48], both implicated in 
the pathogenesis of AAV. 
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Figure 4. NETs induced in vitro by LPS in human neutrophils. NETs are visualised by the 
costaining of neutrophil elastase (green) and nuclear material (DAPI, blue). Reproduced from 
Kaplan et al. [49]. Copyright 2012. The American Association of Immunologists, Inc. 
 
Monocytes also contain ANCA antigens and can be activated by ANCA [50]. ANCA 
activated monocytes release IL-8, a proinflammatory cytokine that attracts and activates 
neutrophils [51]. It also releases monocyte chemoattractant protein – 1 (MCP-1) that attracts 
monocytes and macrophages [52] and may be the reason why AAV lesions fairly quickly 
transform from a neutrophil-rich inflammation to an inflammation dominated by monocytes 
and macrophages. Monocytes are especially found in AAV lesions after the first day or two 
of inflammation and are systemically activated in active AAV [53]. 
1.4.4.4 T and B cells 
Several observations implicate that cell mediated immune responses are important in the 
pathogenesis and exacerbation of AAV. Activation and expansion of thymic-derived 
lymphocytes (T cells) are reported in AAV [54]. This T-cell activation seems to persist 
during remission [55, 56]. Peripheral T cells have been shown to be activated by PR3 [57] . 
In GPA, T cells expressing IL-17 (a cytokine involved in activation of endothelial and 
epithelial cells and attraction of neutrophils) increase [58] and in an animal model of anti-
MPO, necrotising glomerulonephritis IL-17 promoted the development of disease [59]. IL-17 
producing cells have been shown to be major effector cells in autoimmunity in general [60]. 
T-regulatory cells (Tregs) have been reported dysfunctional in AAV and the frequency has 
been reported as increased and decreased by different investigators [61-63]. Although the 
picture is a little bit obscure, there seems to be an imbalance between Tregs and T-effector 
cells in AAV. The lack of function and/or numbers of Tregs may perpetuate ANCA 
formation. 
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The effectiveness of B-cell depletion in AAV as shown in randomised trials has highlighted 
B cells as an important target of therapy [64, 65]. The most obvious role of B cells in the 
pathogenesis of AAV is the production of ANCA. B cells can also interact with T cells and 
contribute to abnormal T-cell function [66].  
B-regulatory cells (Bregs) is a population of B cells characterised by the production of IL 10 
[67]. Bregs seem to have immunoregulatory properties and in animal models ameliorates 
immune response [68]. In patients with active AAV there is a lower percentage of Bregs, 
whereas the percentage of Bregs in patients in remission is normal. Normalisation of Bregs 
after targeted B-cell therapy with rituximab correlated with more effective remission [68, 69]. 
Thus a dysregulation between pathogenic and protective B-cell functions seems to be a 
feature of active AAV. 
1.4.4.5 Cytokines 
In order to activate neutrophils in vitro with ANCA, it is necessary to prime them with a 
proinflammatory stimuli, such as circulating tumour necrosis factor – α (TNF-α) [37], 
bacterial lipopolysaccharide (LPS) [70] or C5a [71]. When mice with anti-MPO IgG induced 
pauci-immune glomerulonephritis were injected with LPS as a proinflammatory stimulus it 
aggravated the glomerulonephritis causing increased amounts of glomerular crescent 
formation and glomerular necrosis. There was also an immediate, transient induction of TNF-
α. Anti-TNF-α treatment attenuated, but did not prevent, the LPS-mediated aggravation of the 
glomerulonephritis [70]. This demonstrates the importance of proinflammatory cytokines, at 
least TNF-α, in the pathogenesis of AAV.  
Other implicated cytokines include the monocyte-derived IL-8 that attracts and activates 
neutrophils [51] and the monocyte chemoattractant protein-1 (MCP-1) that attracts 
monocytes and macrophages [52]. 
Novel proinflammatory mediators have gained a lot of interest in the field of autoimmunity, 
although they have been little studied in AAV. These include high mobility group box 1 
(HMGB1), macrophage migration inhibitory factor (MIF), pentraxin – 3 (PTX3) and soluble 
tumour necrosis factor-like weak inducer of apoptosis (sTWEAK). 
HMGB1 is a nuclear protein known as a transcription and growth factor [72]. HMGB1 is 
actively secreted by innate immune cells such as macrophages and monocytes upon 
endotoxin stimulation, is passively released by injured and necrotic cells, and has been shown 
to stimulate necrosis-induced inflammation [73-75]. Extracellular HMGB1 can act as a 
chemoattractant for leucocytes and as a proinflammatory mediator stimulating release of 
TNF-α and other cytokines [76]. HMGB1 exists in several redox forms with different 
biological activities [77]. For instance, HMGB1 release after apoptosis is substantial but fails 
to stimulate TNF release, whereas HMGB1 release from necrotic cells is a potent stimulator 
of TNF production in responding macrophages, depending on different oxidation states of the 
cysteine residue at position 106 [77]. HMGB1 has previously been studied in 
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proinflammatory conditions such as systemic lupus erythomtousus (SLE), rheumatoid 
arthritis (RA), sepsis and chronic kidney disease [75, 78-81]. 
MIF is an upstream proinflammatory mediator stimulating the release of multiple cytokines 
including TNF-α and it promotes the recruitment of neutrophils into inflammatory sites in a 
chemokine-like fashion [82]. Three-dimensional X-ray crystallography has revealed that the 
MIF molecule contains a hydrophobic pocket [83]. This hydrophobic pocket is likely to play 
an important role in MIF activity, as compounds binding to this region decrease downstream 
MIF signalling [84]. Thyroxin (T4) has been proven to bind to this pocket thereby inhibiting 
MIF in a dose-dependent manner. This interaction is highly specific and the structurally 
similar triiodothyronine (T3) is only a weak inhibitor of MIF [85]. MIF has been implicated 
in the pathogenesis of sepsis, autoimmune diseases such as RA, SLE, cardiovascular disease 
and chronic kidney disease [86-90]. 
PTX3 is a CRP-like protein, but unlike CRP it is produced locally at sites of inflammation in 
response to TNF-α, IL-1 and LPS amongst others and it is not induced by IL6. Neutrophils 
store vast amounts of PTX3 in specific granules that are released upon respiratory burst and 
some of the released PTX3 stays associated with the parent cell by means of NETs [91]. 
PTX3s biological functions include C1q-mediated activation of the complement system 
through the classical pathway and the facilitation of pathogen recognition by phagocytes. It 
can also modulate immune response by restricting excess transmigration of neutrophils into 
tissue by interfering with the P-selectin/PSGL1 system [92] and inhibiting the amplification 
loop of the alternative complement pathway [93], thus dampening unwanted dissemination of 
inflammatory reactions. 
sTWEAK is a ubiquitously expressed type II transmembrane glycoprotein of the TNF 
superfamily that circulates in the plasma in a soluble form (sTWEAK). Through binding to 
its receptor Fn14 it mediates its different biological functions including the exacerbation of 
the inflammatory response and tissue remodelling. Fn14 is highly inducible in the context of 
tissue injury and inflammation. The TWEAK/Fn14 pathway works through NF-κβ signalling 
which leads to target gene transcription [94]. sTWEAK is linked to cardiovascular disease, 
renal disease and autoimmune diseases amongst others and anti-TWEAK therapy has been 
tried experimentally in animal models of lupus nephritis [95, 96].  
 
1.4.5 Scoring disease activity and damage 
Since AAV is complex and heterogeneous in presentation, a structural evaluation is crucial 
when studying these diseases. There are two scoring instruments commonly used in research 
to asses disease activity and damage: the Birmingham Vasculitis Activity Score (BVAS) [97] 
and the Vasculitis Damage Index (VDI) [98]. Both have been adopted and used for clinical 
trials. 
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1.4.5.1 Birmingham Vasculitis Score (BVAS) 
The Birmingham Vasculitis Score (BVAS) records signs and symptoms of active disease 
from nine different organ systems. The score is weighted so that more severe symptoms will 
score more points and new or worsening disease will score more points than persistent 
disease. Disease features are only scored when attributable to active vasculitis. There have 
been several versions of the BVAS since it was first introduced in 1994. The latest is version 
3, which consists of 56 items with a maximum score of 63 [99]. 
1.4.5.2 Vasculitis Damage Index (VDI) 
The Vasculitis Damage Index (VDI) records items of damage attributed to vasculitis or its 
treatment [98]. The damage must have occurred since the onset of vasculitis and been present 
for at least three months. Each item will score one point and over time the score can only 
remain unchanged or increase, even if an item of damage has been resolved. 
1.5 TREATMENT OF AAV 
Generally treatment of AAV consists of induction treatment in order to get the patient in 
remission and maintenance treatment in order to avoid relapse. When deciding on the 
appropriate induction treatment it is important to assess disease severity since different levels 
of disease severity respond to different treatment protocols [9]. Modern AAV treatment is 
evidence based and effective although drug toxicity and treatment failure remain a concern. 
Category Definition 
Localised Upper and/or lower respiratory tract disease without any other systemic 
involvement or constitutional symptoms 
Early 
systemic 
Any, without organ-threatening or life-threatening disease 
Generalised Renal or other organ-threatening disease, serum creatinine < 500 µmol/L 
(5.6 mg/dl) 
Severe Renal or other vital organ failure, serum creatinine > 500 µmol/L (5.6 
mg/dl) 
Refractory Progressive disease unresponsive to glucocorticoids and 
cyclophosphamide 
Table 1. EULAR disease categorisation of ANCA associated vasculitis [9]. 
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1.5.1 Induction treatment 
In principal induction treatment is given for 3–6 months and consists of a cytotoxic drug in 
combination with glucocorticoids. In severe disease plasmaphersis is considered [9]. 
1.5.1.1 Cyclophosphamide  
Cyclophosphamide (CYC) was introduced in the 1970s as the first effective AAV treatment 
[100]. It can be given either orally (2 mg/kg/day) or intravenously (15 mg/kg) in pulsed 
therapy in combination with GC. Dose adjustments for age and renal function are generally 
recommended [101, 102]. In pulsed therapy a lower cumulative dose is given and there is less 
leukopenia and presumably less long-term complications [103]. The relapse rate seems to be 
higher with pulsed therapy however, especially in PR3 positive patients [104]. 
CYC metabolites are toxic and can cause haemorrhagic cystitis in the short term and 
malignancy in the long term [105]. For that reason 2-mercaptoethanesulfonate sodium 
(MESNA) is given. Antiemetics against infusion-related nausea and 
trimethoprim/sulphamethoxazole as prophylaxis against Pneumocystis jiroveci are also 
recommended [9]. Monitoring during the induction phase includes blood counts and 
leukopenia may necessitate dose changes or discontinuation of CYC [9, 106].  
1.5.1.2 Rituximab  
Rituximab (RTX) is a monoclonal mouse-human chimeric antibody directed against the CD 
20 antigen on the B-cell surface, resulting in depletion of B cells in peripheral blood. In two 
randomised controlled trials, induction with RTX (375 mg/m2 x IV) in combination with GC 
was equally effective to CYC in achieving remission [64, 65]. The rate of adverse events was 
similar in the two groups. A subgroup analysis suggested that RTX was more effective than 
CYC in relapsing disease [64]. 
Infusion reactions are common in RTX treatment [107] and patients are routinely given 
paracetamol, antihistamines and glucocorticoids before the infusion. Serious adverse events, 
such as hepatitis B reactivation [108, 109] and progressive multifocal leukoencephalopathy 
[110] have also been reported. 
1.5.1.3 Methotrexate  
In a randomised trial of early systemic AAV, methotrexate (MTX) (20-25 mg/week, oral or 
parenteral) was not inferior to CYC and in these circumstances MTX could be used as a less 
toxic alternative [111]. Some patients may respond more slowly to treatment [111] and some 
who develop more severe disease may have to be transferred to CYC or RTX [34]. Adverse 
events are, to some extent, dependent on renal function and include leukopenia, infections 
and hepatotoxicity [106]. 
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1.5.1.4 Glucocorticoids  
Despite being a mainstay of AAV therapy, no randomised trials have examined the role of 
glucocorticoids (GC) in AAV. Conventionally, 1 mg/kg/dag is given in most treatment 
protocols and then tapered out for a period of 6–18 months [111-113]. When a swift response 
is required pulses of methyl prednisolone (250 – 1000 mg) can be given i.v. [114]. It is 
important to consider osteoporosis prophylaxis [115] and monitor for diabetes [116] in all 
patients. 
1.5.1.5 Plasmapheresis  
Plasmapheresis is recommended in patients with severe disease and a creatinine > 500 
µmol/L. This is based on the findings in the MEPEX trial where plasmapheresis (7 sessions 
within 14 days) proved superior to pulse treatment with i.v. methylprednisolone in terms of 
renal survival in the short term although the long-term benefits remain unclear [117, 118]. 
Although not studied in randomised controlled trials most centres will treat patients with lung 
haemorrhages with plasmapheresis based on published case series [119].  
1.5.1.6 Second line therapies 
Mycophenolate mofetil (MMF) has been tested in a randomised trial comparing it to 
cyclophosphamide as an induction agent in AAV. The remission rate and adverse events 
were similar although the study did not prove non-inferior to i.v. CYC (p= 0.06) [120] and 
there was a trend towards more relapses in the MMF-treated patients after 18 months [121].  
In refractory or relapsing disease, RTX has been tested as rescue treatment in several case 
series with good results [108, 109, 122, 123] and as previously mentioned, RTX seemed to be 
superior to CYC in relapsing disease in the RAVE trial [64]. 
Other second line therapies include i.v. immunoglobulin [124], 15-deoxyspergualin [125] and 
anti-thymocyte globulin [126]. 
 
1.5.2 Maintenance treatment 
Maintenance treatment is started when the patient has achieved remission. The purpose of 
maintenance treatment is to avoid relapse. The optimal length of maintenance treatment has 
not been determined but early cessation of therapy is associated with relapse and often 18–24 
months of treatment is recommended [112, 127]. Long-term CYC therapy was previously 
used to maintain remission. Azathioprine (AZA) (2 mg/kg/day) has proven equally effective 
in preventing relapse at 18 months but without some of the drug toxicity concerns associated 
with CYC [112]. Other agents with proven efficacy in randomised trials are MTX (20-25 
mg/kg/week) [128] and leflunomide (Leflunomide (20-30 mg/day) [129, 130]. These three 
agents are today the standard maintenance treatment together with a low dose of GC. MMF 
(2000 mg/day) was not as effective as AZA in maintaining remission in a study of 156 
subjects over 42 months and must be considered as second line therapy [131]. 
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Generally maintenance treatment has been studied after induction with CYC. Little is known 
about maintenance treatment after induction with RTX. Traditional maintenance agents such 
as AZA [132], watchful waiting [133] and pre-emptive treatment with renewed RTX 
treatment every six months [134] have all been used.  
Chronic carriership of Staphylococcus aureus is associated with relapse in GPA patients [18] 
and continuous treatment with trimethoprim/sulphamethoxazole in addition to standard 
therapy may reduce the risk of relapse [135]. 
 
1.6 MONITORING AAV 
Patient with AAV should periodically be evaluated using a structural clinical assessment 
since new organ involvement can develop at any time. In clinical practice, inflammatory 
markers, urine analyses, chest x-ray and renal function, are all helpful in assessing disease 
activity. A rise in ANCA titre may predict relapse but the monitoring of ANCA remains to be 
controversial [11]. 
For patients in remission on maintenance treatment the monitoring of their full blood count 
and liver functions should take place periodically to detect drug toxicity [106] and patients 
with GC therapy should have their blood sugar tested regularly in order to screen for diabetes 
[127].  
Other long-term drug related complications of importance include osteoporosis [115], 
malignancy [50, 136] and gonad failure [137]. In RTX-treated patients transient neutropenia 
[138] and hypogammaglobulinemia [123] can be seen. 
 
1.7 OBJECTIVES OF THE STUDIES 
The overall aim of this study was to investigate the role of novel pro-inflammatory molecules 
and new therapies in AAV in order to optimise treatment, investigate the pathogenesis and 
find new biomarkers in these diseases. 
 
The specific objectives were: 
To study response to treatment in AAV by clinical assessment and routine and novel 
proinflammatory molecules (paper I – IV). 
To study long-term outcome in RTX-treated patients with relapsing or refractory disease in 
order to gain knowledge on long-term outcome, markers of prognosis and adverse events 
(paper II). 
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To study renal tissue expression and serum levels of novel pro-inflammatory molecules 
assumed to be involved in the pathogenesis of AAV in active disease and in remission 
(papers I, III and IV). 
To study the interaction between thyroid hormones and the immune system in active AAV 
and remission (paper III). 
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2 MATERIALS AND METHODS 
2.1 PATIENTS 
2.1.1 The VASKA cohort 
Incident and prevalent AAV patients in the Stockholm area were included in the VASKA 
study in a joint project between the departments of rheumatology and nephrology at 
Karolinska University Hospital. During study visits, patients underwent clinical assessment, 
routine chemistry, immunological testing and microbial serology. Serum, plasma and urine 
research samples were spun and stored at -70° C for later analysis. Inclusion criteria were 
diagnosis of AAV, age of at least 18 years and a positive ANCA for MPO, PR3 or both by 
standard ELISA or capture ELISA methods at any time point. ANCA negative AAV patients 
or patients with anti-GBM antibodies were not included in the study. All patients gave 
informed consent.  
Prevalent patients were assessed at one time-point and incident patients were assessed at 0, 3, 
6, 24 and 60 months. The study is on-going and to date some 280 prevalent and 60 incident 
patients have been included in the study.  
2.1.2 Study patients 
In paper I, 30 patients with available renal biopsies were included. Most of these patients 
were prevalent patients with research data available from previous studies and some were 
incident patients within the VASKA study. In paper II, 15 prevalent patients with relapsing 
disease and one incident patient within the VASKA study who had been treated with RTX as 
a rescue treatment were followed up. In paper III, 27 incident patients were investigated 
regarding MIF and thyroid hormones and in paper IV, 40 incident patients were investigated 
regarding PTX3 and sTWEAK including the 27 patients in study III. 
 
 
 
 
 
 
 
 
 
Paper I, 30 patients 
Paper II, 16 patients 
Paper III, 27 patients 
Paper IV, 40 patients 
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Paper n Age 
(Mean) 
Men/ 
Women 
Diagnosis 
GPA/MPA/EGPA 
ANCA 
PR3/MPO/DP* 
Paper I 30 59.0 14/16 17/12/1 16/12/1 
Paper II 16 56.6 9/7 14/1/1 13/3/0 
Paper III 27 57.5 15/12 17/9/1 15/12/0 
Paper IV 40 58.0 20/20 23/15/1 22/16/1 
*Double positive for both MPO and PR3 
Table 2. Patient characteristics  
2.1.3 Controls 
Randomly selected healthy controls from a population-based cohort in the Stockholm area 
were recruited as a control group in papers I, III and IV. These patients were investigated as 
part of an on-going prospective study [139].  
 
 Paper I Paper III Paper IV 
n 48 53 20 
Age (years) 62 ± 12 60 ± 12 63 ± 12 
Gender (Male, %) 72 68 70 
CRP (mg/L) 1.2 (0.2 – 32.0) 1.2 (0.2 – 32.0) 1.5 (0.8 – 8.1) 
GFR (ml/min/1.73 m2) 85 ± 20 85 ± 20 82 ± 14 
Table 3. Controls’ characteristics. 
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2.2 ASSESSMENT OF DISEASE ACTIVITY AND DAMAGE 
Disease activity was assessed using the 2003 version of the BVAS at all study visits. The 
patients in papers III and IV had this data collected prospectively. Patients in papers I and 
II had the data collected prospectively when available, but in some instances the BVAS was 
estimated retrospectively. A patient with a BVAS of 0 was considered to be in remission and 
in paper II a patient with a reduction of the BVAS of at least 50% was considered to be in 
partial remission. Relapse was defined as an increase in disease activity, reflected in the 
BVAS, and requiring renewed induction treatment. 
Disease and treatment-associated damage was assessed using the VDI. 
2.3 TREATMENT 
Most commonly, patients in the study were treated with pulsed i.v. CYC (15 mg/kg) in 
combination with GC according to EULAR guidelines or MTX (20-25 mg/week) in patients 
with localised or early systemic disease. Refractory or relapsing disease was generally treated 
with RTX 500 mg x II, 1000 mg x II or 375 mg/m2 x IV in combination with GC. Patients 
with a creatinine > 500 µmol/L were given plasmapheresis. Some patients received MMF as 
induction treatment and some received oral CYC. 
Patients in paper II were all given RTX as second line treatment and they had all previously 
received CYC at some time point. 
Patients in remission were given maintenance treatment with MTX, AZA or MMF in 
combination with low dose GC. 
 
2.4 LABORATORY MEASUREMENT 
2.4.1 Routine laboratory parameters 
Routine laboratory analyses were carried out using standard methods and these included 
CRP, albumin, creatinine, sedimentation rate (SR), urine dip slide, urine sediment and 
quantification of proteinuria by 24-hour urine-albumin excretion or creatinine/albumin ratio 
in morning urine. Estimated GFR (eGFR) was calculated using the Modification of Diet in 
Renal Disease (MDRD) formula [140]. 
2.4.2 ANCA 
ANCA was analysed at all study visits using standard ELISA methods (direct ELISA, Euro 
diagnostic) or multiplex (BIO-RAD, BioPlex TM 2200). ). IF ANCA was not routinely 
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carried out. In selected cases, a capture PR3 ANCA was carried out at the discretion of the 
treating physician with the Wieslab Capture PR-3 ANCA kit (Eurodiagnostica AB, Malmoe, 
Sweden All patients in the studies had had a positive ANCA test at some time point. 
2.4.3 Analysis of HMGB1 
Serum levels of HMGB1 were analysed from cryopreserved serum by Western blot 
(Amersham Biosciences) and performed at The Feinstein Institute for Medical Research, 
New York, USA. 
2.4.4 Analysis of MIF, PTX3 and sTWEAK 
MIF, PTX3 and sTWEAK were analysed in serum using commercially available ELISA kits. 
In addition, PTX3 was measured in urine. ELISA kits for MIF were provided by Young In 
Frontier Co. Ltd. (Seoul, Korea), ELISA kits for PTX3 by R&D Systems Europe Ltd. 
(Abington, UK) and ELISA kits for sTWEAK by Bioscience (Hatfield, UK). All these 
analyses were carried out at the renal lab, KFC, Karolinska Institutet. 
 
2.5 HISTOLOGICAL ASSESSMENT 
 
Renal biopsies in paper I were performed by percutaneous ultrasonography-guided puncture. 
The renal tissue obtained was evaluated by light microscopy, immunofluorescence (IF) and 
electron microscopy according to standard techniques. Patients displaying pauci-immune 
focal necrotising glomerulonephritis or crescentic glomerulonephritis were considered as 
having active renal AAV and patients with the absence of these lesions were considered to be 
in renal remission. 
Immunohistochemical stainings were performed using a monoclonal mouse IgG2b anti-
HMGB1 antibody (Critical Therapeutics, Lexington, KY, USA) and Alexa Fluor© 488 
conjugated goat anti-mouse IgG2b antibody (Molecular probes, Invitrogen, Eugene, OR, 
USA) for detection (figure 5a). 
On paraffin embedded sections of renal tissue a biotin-labelled horse anti-mouse antibody 
(Vector laboratories Inc.) containing 2% normal horse serum was used for detection (figure 
5b). 
 
2.5 STATISTICS 
Normally distributed variables were expressed as means ± SD (unless noted otherwise), and 
non-normally distributed variables were expressed as medians and ranges. Differences 
between the time points were examined using the Kruskal-Wallis analysis of variance 
(ANOVA), followed by a post hoc Dunn’s test for non-parametric comparisons. A χ2 test was 
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used for categorical variables. Correlations (ρ) were calculated by using the non-parametric 
Spearman rank test. A multivariate general linear model was used to assess the relationship 
between HMGB1 and various subgroups of vasculitis adjusting for eGFR. In paper II 
changes in CRP and BVAS were analysed by a Student’s t-test. Statistical significance was 
set at a level of p < 0.05. All statistical analyses were performed using SAS statistical 
software (SAS Institute Inc., Cary, NC, USA). 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic 
cytoplasmic antibody (ANCA)-associated vasculitis with renal manifestations  
High-mobility group box-1 protein (HMGB1) is a protein, or rather a group of proteins, that 
has gained a lot of attention in the field of autoimmunity. One of the reasons is that it seems 
to provide an answer to a key question in autoimmunity – how does a sterile inflammation 
arise? HMGB1 is a cytokine actively secreted in response to invading pathogens, but it is also 
released from dying and injured cells [76]. This means that products from cellular injury 
produced by the host (as in ischemia for instance) can give rise to an immune reaction 
indistinguishable from infection. 
In this study 30 AAV patients with renal manifestations were included in the study at the time 
of renal biopsy with simultaneous collection of serum samples and evaluation of disease 
activity. In seven of the cases follow-up biopsies 6–9 months later were available with paired 
samples at these two time points.  
A total of 38 biopsies showed active renal AAV in 25 cases and inactive in 13 cases. HMGB1 
was significantly higher in active cases compared to inactive ones (120 +/- 48 ng/ml vs. 78 
+/- 46 ng/ml, p = 0.01) and in the paired samples HMGB1 was significantly higher at 
baseline than after treatment and in remission 6-9 months later. HMGB1 staining appeared 
stronger with a more distinct extranuclear staining pattern in active disease than in remission. 
HMGB1 levels were much higher in AAV patients than in healthy controls (10.9 +/- 10.5 
ng/ml), regardless of whether they were in remission or not. CRP and SR were significantly 
lower in inactive disease compared to active disease but did not significantly correlate with 
HMGB1. There was no statistically significant difference in HMGB1 levels between 
subgroups of AAV (GPA vs. MPA vs. EGPA) as has been proposed by other investigators 
[141], nor was there any difference between PR3 or MPO positivity. 
 
 
 
 
 24 
 
 
Figure 5a. Expression of extranuclear HMGB1 in necrotising renal AAV in paired kidney biopsies 
(active disease on the left and remission on the right). 
 
 
Figure 5b. Expression of extranuclear HMGB1 in necrotising renal AAV. Immunohistochemistry on 
paraffin embedded renal tissue. Active renal AAV on the left and healthy control on the right. 
Previously unpublished. 
In conclusion, we found increased levels of HMGB1 in active renal AAV compared to 
inactive AAV and increased expression of HMGB1 in renal tissue in active disease clearly 
implicating HMGB1 in the pathogenesis of AAV. It is not clear whether increased serum 
levels of HMGB1 mainly derive from the kidney or other manifestations of the disease but 
the notion that necrotic tissue found in granulomatous disease (GPA) is the reason why 
excess amounts of HMGB1 are seen in AAV, as proposed by Wibisono et al. [141] is not 
supported by our data [142]. We did however find a higher level of HMGB1 in patients with 
pulmonary disease, but no correlation to granuloma, suggesting that the total burden of 
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disease is important. The discrepancy between our findings could be due to different methods 
in measuring HMGB1; we used a western blot method previously described [80] as opposed 
to an ELISA method used by Wibisono et al.  
Levels of HMGB1 were much higher in AAV compared to healthy controls even when there 
was no clinically active disease, a finding that has been replicated in a cohort of SLE patients 
[78]. At the time, this result was puzzling but recent advances within the field of HMGB1 
biology has shown that there are different forms of HMGB1 with different biological activity 
depending on the oxidative state of three cysteine residues within the molecule. Apoptotic 
cells oxidise the cysteine residue at position 106, creating a molecule without the 
proinflammatory properties of HMGB1 released by necrotic cells and secreted by 
inflammatory cells [77]. It is possible that the high levels of HMGB1 seen in inactive AAV 
derive from apoptotic cells but that needs to be confirmed in future studies.  
3.2 PAPER II 
Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 
patients 
CYC is generally considered standard treatment of AAV but a small subset of patients is 
refractory or intolerant to this treatment. In these circumstances, RTX is often used as rescue 
therapy [122, 143, 144]. We wanted to study the outcome of these patients and identified 16 
patients among our vasculitis patients who had received RTX on this indication and included 
them in the study. 
We found that RTX was effective in this subset of patients that are otherwise difficult to 
manage. Twelve patients achieved complete remission and three patients achieved partial 
remission. During follow-up six patients relapsed. Patients positive for PR3 ANCA in the 
capture assay but not conventional ELISA seemed to be at risk of relapse. We could identify 
five such patients within our study. Four relapsed and the fifth received RTX every six 
months as pre-emptive therapy. Capture ANCA recognises different epitopes compared to 
conventional ANCA and it has previously been reported that capture ANCA is more effective 
in predicting relapse [145]. This could be consistent with the idea that different ANCA 
epitopes have different pathogenic effects [15, 146], but further conclusions from our study 
are limited by the sample size. 
Infectious complications were a concern in the study and there were two cases of hepatitis B 
reactivation. One of the patients presented with elevated liver enzymes within two weeks of 
rituximab administration. Viral serology revealed anti-HBsAg positivity and HbeAg 
positivity. Virus load was quantified to 33.6 million copies of Hepatitis B virus per ml. blood. 
There was a hepatitis B serology 10 years prior to the rituximab treatment positive for anti-
HbcAg and anti-HbsAg. The other patient received rituximab without any complication but 
on follow-up it was noted that the patient converted from anti-HbsAg and HbeAg negativity 
to positivity. The patient was anti-HbcAg positive at treatment start. Quantification showed > 
110 million copies of hepatitis B virus per ml. blood. Both patients received antiviral 
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treatment with good control of viral load. Hepatitis B reactivation has mainly been reported in 
lymphoma treatment [147] but our data highlights the importance of assessing hepatitis B 
status and prescribing antiviral prophylaxis for patients at risk. 
Other infectious complications included fatal sepsis, invasive fungus infection and CMV 
retinitis.  
The efficacy and safety of RTX has been confirmed in randomised controlled trials, and in a 
subgroup analysis RTX appeared more effective in treating relapses [64, 65]. In our study 
RTX seems to be effective as rescue therapy but it also indicates that RTX treatment with 
other concurrent immunosuppression may be associated with a risk of serious infections.  
3.3 PAPER III 
Macrophage Migration Inhibitory Factor (MIF) and Thyroid Hormone Alterations in 
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV) 
We investigated MIF in a prospective study of 27 incident patients before and after induction 
treatment (at 0, 3 and 6 months). There is a known interaction between thyroxine and MIF 
[85] and AAV is associated with thyroid disease and its treatment [32, 148]. We therefore 
assessed thyroid status as well along with CRP, creatinine, albumin and urine status. Disease 
activity was assessed using the BVAS 2003 at all time points and damage using the VDI. 
MIF and GC have reciprocal effects and it has been reported that MIF is inducible by GC 
[149]. Therefore exposure to GC was calculated and correlated with MIF levels. 
We found that levels of MIF significantly decreased after induction treatment 8.6 pg/mL at 
baseline vs 5.7 pg/mL at 3 months and 6.2 pg/mL at 6 months (p=0.001) independently of 
CRP, creatinine, organ involvement or exposure to GC.  Levels of MIF were much higher in 
AAV patients than controls regardless of whether they were clinically active or not.  
T3 was depressed at baseline and increased during treatment similar to the thyroid alterations 
seen in critically ill patients, so-called ”Euthyroid sick syndrome” [150]. T3 correlated 
inversely with the BVAS, so these alterations were more pronounced in the most ill patients. 
MIF did not correlate with GC, perhaps because GC dosing was unphysiologically high at the 
time of sampling. There was a strong correlation between the baseline MIF/T4 ratio and the 
MIF/T4 ratio at 6 months indicating an interaction between these molecules. 
In conclusion, MIF is elevated in active AAV compared to remission and healthy controls 
indicating that MIF may be implicated in the pathogenesis and exacerbation of AAV. There 
seems to be an interaction between MIF and thyroxine as previously described in sepsis [85]. 
In animal models of sepsis, anti MIF treatment improves survival [85]. It is unknown whether 
anti MIF treatment would also be beneficial in AAV but this would be an excellent topic for 
future studies, since both animal models and anti MIF treatment exists [151]. The MIF – 
thyroxine interaction offers a possible causal link between AAV and thyroid disease. 
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3.4 PAPER IV 
PTX3 and soluble TWEAK levels in active ANCA associated vasculitis (AAV) patients 
undergoing treatment – correlation to disease activity and relapse 
In paper IV we examined the novel proinflammatory molecules PTX3 and sTWEAK in 
AAV. To do so we recruited 40 patients with active AAV (33 newly diagnosed, seven 
relapses) and measured levels of PTX3 and sTWEAK before and after induction treatment (at 
baseline and after six months) along with CRP, creatinine, urine samples and albumin. 
Disease activity was assessed at 0, 3 and 6 months. At three months, creatinine and urine 
samples were obtained for disease assessment purposes. 
We found that PTX3 was elevated at baseline compared to follow-up (4.66 ng/ml vs.1.75 
ng/ml p < 0.001) and that PTX3 correlated with disease activity but not with CRP or 
creatinine. The patients who were in remission at three months had a higher PTX3 level at 
baseline than the patients who failed to achieve remission: 5.3 ng/ml vs. 2.6 ng/ml (p = 0.05), 
at six months the difference was 4.8 ng/ml vs. 3.8 ng/ml (P=0.67). Urine levels of PTX3 were 
generally below detection threshold, even in patients with renal AAV. 
 
Figure 6. PTX3 levels at baseline and at follow-up. 
 
In neutrophils, PTX3 is stored in specific granules that are released upon respiratory burst and 
can be found in the proximity of netting neutrophils [91], thus levels of PTX3 may reflect 
neutrophil reactivity in AAV. The correlation between disease activity and PTX3 levels may 
implicate PTX3 in the pathogenesis of AAV. PTX3 has proinflammatory properties but there 
is data that suggests that it actually may be protective by dampening the p-selectin function 
and thus recruitment and extravasation of leukocytes [92]. PTX3 also inhibits the 
amplification of the alternative complement pathway through interaction with factor H [152]. 
In light of this it is particularly interesting that high PTX3 in our study seemed to be 
associated with a more favourable prognosis suggesting that the role of PTX3 is of a more 
regulatory nature. 
Our data thus suggests that PTX3 may be worth exploring as a marker of disease.   
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The other molecule we were interested in was sTWEAK. We found that sTWEAK did not 
significantly change throughout the study and that levels in AAV appeared similar to controls 
(566.6 pg/ml at baseline and 558.7 pg/ml at six months compared to 522.5 pg/ml in controls), 
however patients who failed to achieve remission at three and six months (BVAS > 0) had a 
significantly higher level of sTWEAK at baseline.  
 
 
Figure 7. sTWEAK levels in healthy subjects, at baseline and at follow-up. 
sTWEAK biology is firmly connected to its receptor, Fn14. A lot of work has been done on 
renal injury, and it has been shown that Fn14 in particular is upregulated in renal injury of 
various sorts [94]. We therefore separated out the patients with renal involvement and found a 
trend towards lower sTWEAK levels in these patients compared to patients without renal 
involvement (p = 0.06).  In patients with renal vasculitis, sTWEAK levels increased after 
treatment and finally in patients without renal manifestations, levels fell after treatment 
although this did not reach significance.  
 
Figure 8. sTWEAK levels in controls, patients without renal vasculitis (NR) and patients with renal 
vasculitis (R). 
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Our data implies that sTWEAK has a tendency to vary with the phenotype of AAV and that 
sTWEAK may be involved in renal AAV, however that remains to be confirmed in a larger 
study. 
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4 GENERAL DISCUSSION 
4.1 METHODOLOGICAL CONSIDERATIONS 
4.1.1 Patient cohort 
The ANCA associated vasculitides are rare and heterogeneous in presentation. The catchment 
area of Karolinska University Hospital is approximately 1.500.000 people. More or less all of 
the adult AAV patients are treated at the departments of rheumatology and nephrology and 
most were screened for inclusion in the VASKA study. Although a few patients declined 
participation and others were not enrolled as prevalent patients due to comorbidities, 
advanced age or social factors that would hinder follow-up, the cohort is highly 
representative of the spectrum of disease in our population. It is also a cohort of considerable 
size considering the rarity of these diseases. Few patients are lost to follow-up, partly on 
account of our general policy to never dismiss or refer these patients to general practitioners.  
In the cohort there is a predominance of GPA, reflecting the fact that Scandinavia is a high 
endemic area of GPA [22]. Furthermore, we included relapses as incident patients, and 
relapses occur more frequently in GPA patients [26].  
4.1.2 Treatment and response 
With the exception of a few cases that were enrolled in international multicentre studies, all 
therapy decisions regarding the patients in this thesis were made by the treating clinician. 
Generally, treatment followed international guidelines. In systemic disease CYC was 
considered standard therapy and RTX was rarely used in novel patients. Dosage was 
generally according to EULAR guidelines [9], the main exception being RTX, where dosage 
varied considerably. 
Obviously there are different treatment protocols for different phenotypes of the disease and 
since we tried to include all patients presenting with AAV willing to participate in the study, 
there was an intrinsic heterogeneity of treatment.  
In refractory or relapsing disease, a topic explored in paper II, several immunosuppressive 
drugs were used concurrently and GC dosage varied considerably.  
There were somewhat different response criteria in the studies. In paper IV patients were 
considered to be in remission if the BVAS was 0. In paper II patients were considered to be 
in complete remission if the BVAS was 0 and partial remission if there was a reduction of the 
BVAS of at least 50% (in concordance with definitions by previous investigators). Patients 
could still be on GC and considered to be in remission. Patients failing to achieve remission 
in papers III and IV were all on CYC as the original treatment and typically switched to 
RTX. 
  31 
4.1.3 Strengths and limitations 
This thesis is based on observational studies with the limitations that are associated with such 
studies. There is a clear possibility that the different treatment protocols used had an impact 
on the results, especially when measuring sTWEAK in renal and non-renal AAV. Exposure 
to GC also differed somewhat at baseline in papers I, III and IV although efforts have been 
made to secure samples at the earliest possible time point. A limited number of investigators 
who all had previous training and clinical experience of AAV carried out disease assessment. 
There were also some cases in papers I and II where the BVAS was estimated 
retrospectively, which could have influenced the quality of assessment. 
In Paper II we investigated a highly selective subset of patients who were difficult to 
manage. Concurrent medication most certainly affected the result in terms of remission 
induction and adverse events. The number of patients was limited and the study was 
uncontrolled. Even though the study was descriptive in nature the cases were representative 
of how RTX is used in “real life” as a second line treatment, at least in our clinics.  
In Papers I, III and IV proinflammatory molecules are measured before and after treatment 
and in some cases in healthy controls. An association between the molecule investigated and 
disease activity may suggest that the molecule is implied in the pathogenesis of the disease 
but it says little of the nature of that involvement regarding cause and effect. In this respect 
our results are hypothesis generating and should be followed by further studies. 
A strength in papers III and IV is that the data is prospectively collected and that no patients 
within the cohort were excluded, thus reflecting a clinically relevant setting. Considering how 
rare these diseases are and that the thesis is based on a single centre cohort, it is a reasonable 
number of subjects. Patients in paper II reflect all consecutive AAV patients treated with 
RTX up to that time point at our clinics, giving it considerable descriptive power of RTX use 
in “real life” as second line therapy. 
Our results from paper I, II and IV suggest that some of the molecules investigated may be 
used as biomarkers, however a promising biomarker candidate should be evaluated in 
subsequent studies. 
As discussed elsewhere, HMGB1 was measured using a western blot in paper I. Recent 
findings have shown that the HMGB1 molecule exhibits different red-ox forms with different 
biological activity which this method does not discriminate between, making the results in 
paper I more difficult in interpret.  
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4.2 FINDINGS AND IMPLICATIONS 
4.2.1 Persistently elevated levels of proinflammatory molecules after 
treatment 
When comparing levels of the proinflammatory mediator MIF and HMGB1 to healthy 
controls we found persistently elevated levels even when disease was in remission. In fact the 
difference between patients in remission and healthy controls was more pronounced than the 
difference between active and inactive disease. In the case of HMGB1, newer findings have 
highlighted the importance of different isoforms of the molecule for the biological activity 
[77]. It is possible that we mainly see biologically inactive oxidised HMGB1 derived from 
apoptotic cells in inactive AAV. Although we did not find a correlation between MIF levels 
and glucocorticoid dosage there is a theoretical possibility of induction of corticosteroids 
[149] since patients were typically treated with 5-10 mg of prednisolone at follow-up. We did 
not measure PTX3 in healthy controls, but in a previously published paper PTX3 levels were 
similar to healthy controls in quiescent disease [153]. In this respect, PTX3 seems to more 
closely reflect disease activity than HMGB1 and MIF. 
Another possible explanation of the elevated levels of HMGB1 and MIF is that we see many 
of the features of active disease still present in remission, but essential components necessary 
for the exacerbation of the disease, such as activated neutrophils, are lacking. This may 
predispose for relapse when discontinuing immunosuppression or when exposed to a disease-
triggering event. It is also possible that this chronic inflammation enhances the progression of 
other vascular disorders such as cardiovascular disease [154-156] in concordance with what 
we see in other autoimmune systemic diseases such as SLE [157]. This is of particular 
interest in view of the higher incidence of stroke, heart infarction and accelerated 
atherosclerosis we see in AAV [155].  
4.2.2 The role of rituximab as rescue treatment 
RTX was originally licenced for treatment of B-cell lymphoma in 1997 [158]. It proved to be 
effective in autoimmune diseases as well and in 2006 it was licenced for RA [107]. In the 
lack of established second line therapies, off label prescription of RTX in AAV started to 
emerge as a form of rescue therapy. In published case series, RTX proved effective in 
inducing remission [109, 122, 143, 144, 159]. A significant proportion of the patients 
relapsed, often around the time point of B-cell return, but retreatment with RTX was 
generally effective. Based on these promising early experiences two randomised controlled 
trials were conducted comparing RTX with CYC [64, 65]. The AAV-patients included in 
these studies were newly diagnosed or relapsing and the studies showed that RTX was non-
inferior to CYC as an induction agent. In relapsing patients it was in fact more effective than 
CYC [64]. These results have led to the common practice of using RTX as the treatment of 
choice for relapsing patients and in many ways RTX has revolutionised the management of 
difficult AAV cases [160]. Adverse events are however not less common with RTX and 
established maintenance treatment after RTX is lacking [64]. In paper II we report two cases 
of hepatitis B reactivations in RTX-treated patients among other serious adverse events. Early 
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on RTX was often used in combination with CYC [65]. The rationale for this was concern 
that the effect of rituximab was delayed in comparison to CYC. Our case series and others 
suggest that the combination of RTX and CYC may carry an increased risk of complications. 
This is not trivial since treatment is a major cause of morbidity and mortality associated with 
these diseases [161, 162], and during the first year after diagnosis, treatment-related deaths 
are by far more common than disease-related deaths [163].  
In our case series and others there are patients treated and retreated with rituximab several 
times. Although there is a risk of hypogammaglobulinemia, (which is considered to be a 
relative contraindication for further treatments), clinical experience in AAV and other 
diseases such as RA supports multiple treatments with little risk to the patient [134]. This is 
significantly different when compared to CYC, where cumulative dose quickly becomes an 
issue. 
4.2.3 Biomarkers 
In the diagnosis of AAV, ANCA is very helpful and in a high proportion of patients ANCA is 
positive at the time of diagnosis, in particular in patients with systemic angiitis [164]. 
Subsequent monitoring of ANCA remains controversial, as titres do not always reflect 
disease activity [145, 165]. Previous investigators have found that capture ANCA is more 
sensitive without loss of specificity [7]. Albeit based on few cases, our study strengthens the 
notion that AAV patients with a negative conventional ANCA and positive capture ANCA 
may be at increased risk of relapse and should be monitored more closely. 
In clinical practice CRP and sometimes sedimentation rate (SR) are followed. Although 
inflammation parameters are typically increased in active disease, these are crude markers of 
general inflammation and of little help in discriminating relapse from infection. CRP is also 
affected by corticosteroids and SR is commonly elevated in patients with impaired renal 
function and/or proteinuria [166]. Thrombocytosis is a common finding in AAV but 
unspecific and of little help in the clinical setting.  
We have found three molecules that are all increased in active AAV compared to inactive 
AAV: HMGB1, MIF and PTX3. MIF correlated with disease activity at presentation and 
dropped after treatment reflecting less or no disease activity. A  previous investigator has 
suggested that MIF may be a marker of disease worth exploring in AAV [167]. Any potential 
application in the clinic would be limited by the fact that we see persistently elevated levels 
of MIF in inactive disease compared to controls. GC, commonly used during the maintenance 
phase of treatment, also potentially affects MIF [149]. HMGB1 is also elevated in inactive 
AAV and there are several isoforms with different biological activity, limiting any 
conclusions regarding the molecules utility as a biomarker [77]. Recently it has been 
described that HMGB1 levels in urine are elevated in patients with active renal AAV 
compared to remission and healthy controls [168]. 
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PTX3 has several interesting properties making it a candidate biomarker. It correlates well 
with disease activity independently of CRP and creatinine. It is not elevated in patients in 
remission. It is locally produced at sites of inflammation and it is unaffected by GC. 
Urine samples are always investigated in AAV patients and haematuria is highly suggestive 
of glomerulonephritis. In a patient with renal AAV, haematuria and proteinuria is often 
persistent after induction treatment and may resolve several months after the patient has 
entered remission. We measured PTX3 in urine as well, but we could not consistently find 
elevated levels in patients with active renal disease. This may be due to tubular reabsorption.  
sTWEAK did not correlate with disease activity and in that respect would make a poor 
biomarker. High levels of sTWEAK seemed to represent a phenotype of AAV with less 
favourable outcome in terms of remission. This is not as clear-cut as the difference between 
GPA and MPA as there was no clear difference in sTWEAK levels between these entities. 
Further conclusions are somewhat limited by the different treatment regimes.  
4.2.4 Outcome and prognosis 
Predicting outcome for the individual AAV patient is notoriously difficult. Airway 
granuloma, PR3 positivity and GPA diagnosis is associated with relapse but not necessarily 
with damage and mortality [25, 169, 170]. In fact, MPA seems to have a worse prognosis in 
this respect, most likely due to age and renal function [29, 171]. There are some observations 
in our studies that may relate to prognosis in terms of relapse and management of relapsing 
patients. Firstly, as discussed elsewhere, RTX is an excellent addition in the therapy arsenal 
in AAV, not least in relapsing patients who can be treated several times with good effect and 
with little toxicity. It is reasonable to assume that RTX treatment in this subset of patients 
results in lowered accumulative damage. Secondly, we observed that positive capture PR3 
ANCA in the absence of a positive conventional ANCA was found in several relapsing, 
RTX-treated patients. And finally we saw that patients with high sTWEAK levels and low 
PTX3 levels at treatment start were less likely to achieve remission with standard treatment 
than other patients. 
4.2.5 Future perspectives 
Our studies suggest a potential role for a number of proinflammatory molecules in the 
pathogenesis and exacerbation of AAV and several of the findings merit further studies. In 
paper I we found elevated levels of HMGB1 in active disease compared to inactive and 
much higher levels of HMGB1 in patients in remission compared to healthy controls. Recent 
findings have shown that HMGB1 is actually a family of molecules with different redox 
states and biological functions [77]. This raises the question as to whether we see different 
redox states of HMGB1 in patients in remission and in active disease. Ideally, HMGB1 
should be reanalysed with respect to the different redox forms in AAV patients. 
In paper III, we see a clear indication of an interaction between MIF and thyroxine. This 
interaction has been demonstrated previously in sepsis and in animal models of sepsis 
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inhibition of MIF with biologically inert D-thyroxine (as opposed to the biologically active L-
thyroxine) improved survival [85]. There are excellent and well-characterised animal models 
of MPO-mediated vasculitis [172]. A logical continuation of our research would be to feed 
MPO-vasculitis prone animals with D-thyroxine and compare them with untreated animals, 
with the hypothesis that MIF inhibition would diminish vasculitis activity. 
The discrimination between remission and relapse is sometimes challenging and in addition 
there is a need to assess disease activity at any given time point in order to guide therapy. 
Today, there is a lack of reliable biomarkers in AAV presumably resulting in overuse and 
underuse of potentially harmful drugs resulting finally in increased morbidity and mortality. 
Of the molecules we investigated, PTX3 has shown the most promise as a marker of disease 
and should be evaluated in a larger study.  
sTWEAK seems to be implicated in renal vasculitis, as in other kidney diseases. This could 
be further investigated by immunohistochemistry of TWEAK and the receptor, Fn 14, in 
renal biopsies from active disease and remission in analogy with our previous work on 
HMGB1. 
As therapy becomes more effective in controlling disease, the research focus should shift 
somewhat to prevent long-term consequences such as diabetes, infections, cardiovascular 
disease, renal impairment and malignancies [161, 173-175]. One way is to optimise 
immunosuppressive therapy. Today, patients are to a large extent treated with “one size fits 
all” immunosuppressive therapy. This is not least the case with respect to GC. Tailoring 
treatment is a challenge for the future.  
Most research today is carried out on active AAV but as our work and that of others 
highlights, there are immunological alterations in quiescent disease that may predispose 
patients for relapse and possible other diseases such as myocardial infarction and stroke. 
Better understanding of the immunological pathology in remission may help predict relapse 
as well as in finding targets for the prevention of cardiovascular disease in AAV patients.  
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5 CONCLUSIONS 
 
AAV patients in remission still have persistent inflammation and signs of immune 
dysregulation compared to healthy subjects. 
The proinflammatory molecules HMGB1, MIF and PTX3 are elevated in active AAV 
compared to remission, supporting the view that they may be involved in the pathogenesis 
and exacerbation of AAV. The increased tissue expression of HMGB1 in active ANCA 
associated renal vasculitis strongly supports a role of HMGB1 in the inflammatory process of 
pauci immune glomerulonephritis. 
Thyroid hormone alterations are seen in AAV patients in concurrence with what is seen in 
critically ill patients and the known interaction between MIF and thyroxine may also be of 
clinical importance in AAV patients. 
PTX3 is a potential biomarker in AAV and should be evaluated for that purpose in further 
studies. The sTWEAK/Fn14 system is implicated in renal vasculitis and should be further 
investigated, not least since TWEAK is a potential target of therapy. 
RTX is an effective treatment in relapsing or refractory AAV but infectious complications are 
a concern. Concurrent immunosuppression may be a risk in these circumstances and it is 
important to assess hepatitis B status before treatment. 
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6 SVENSK SAMMANFATTNING 
 
ANCA associerade vaskuliter (AAV) är en grupp ovanliga autoimmuna sjukdomar som 
drabbar kroppens minsta blodkärl och ibland också leder till inflammationshärdar 
(granulom), framför allt i övre och nedre luftvägar. Typiskt för AAV är förekomsten av 
ANCA, vilket är antikroppar som är riktade mot kroppsegna proteiner som normalt sett 
återfinns inuti vissa typer av vita blodkroppar (neutrofiler). Obehandlad leder sjukdomen till 
skador på inre organ och död inom något år, men med modern behandling kan nästan alla 
patienter bli fria från sjukdomsaktivitet. Oftast består behandlingen av ett cellgift i 
kombination med kortison vilket dämpar immunförsvaret och den autoimmuna reaktionen. 
Infektioner, läkemedelsbiverkningar och återfall i sjukdomen är problem som fortfarande är 
olösta och är föremål för mycket forskning. Eftersom symptomen av sjukdomen ofta kan vara 
svårtolkade för patient och doktor påbörjas behandling ibland för sent, då organskada redan 
utvecklats och AAV är en inte helt ovanlig orsak till att man behöver dialysbehandling. 
Syftet med den här avhandlingen var att undersöka ett antal nykarakteriserade molekyler som 
man vet driver inflammation i andra, närbesläktade sjukdomar och se om dessa verkar vara 
inblandade i AAV också. Vi ville också undersöka effekten av nya behandlingar. 
I den första artikeln undersökte vi molekylen HMGB1 och fann att nivåerna var högre hos 
patienter med aktiv sjukdom än hos patienter med behandlad sjukdom. När vi undersökte 
material från njurbiopsier fann vi att cellerna producerade mycket större mängder HMGB1 
hos patienter som hade en aktiv vaskulit i njuren. 
I den andra artikeln följde vi upp patienter med svårbehandlad sjukdom som inte hade haft 
fullgod effekt av cellgiftet cyklofosfamid och därför fått behandling riktad mot 
antikroppsproducerande vita blodkroppar (B-celler) med medicinen rituximab (Mabthera©). 
Vi fann att rituximab verkade vara effektivt hos dessa annars svårbehandlade patienter, men 
att det fanns en risk för allvarliga infektioner, speciellt då rituximab kombinerades med 
cellgifter. 
I den tredje artikeln undersökte vi molekylen MIF och sköldkörtelhormoner vid AAV och 
fann att MIF nivåerna följde sjukdomsaktiviteten och att man kunde se förändringar i 
sköldkörtelhormoner som man normalt bara ser hos svårt sjuka patienter, till exempel 
patienter med blodförgiftning. Vi fann också tecken till att MIF och sköldkörtelhormoner 
interagerade med varandra, vilket är ett exempel på hur sköldkörtelhormoner kan påverka 
immunförsvaret. 
Slutligen, i den fjärde artikeln undersökte vi molekylerna PTX3 och sTWEAK och fann att 
PTX3 korrelerade med sjukdomsaktivitet och att det finns tecken till att PTX3 kan vara 
skyddande vid AAV. sTWEAK föreföll vara inblandad i njurvaskulit och höga nivåer innan 
behandling verkade vara associerat med sämre behandlingssvar. 
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Sammanfattningsvis har vi funnit flera molekyler som verkar vara inblandade i uppkomst och 
utveckling av AAV. I framtiden kan dessa molekyler kanske underlätta diagnos av 
nyinsjuknade, följa sjukdomsförlopp eller skräddarsy behandling. De är också möjliga 
måltavlor för behandling med nya läkemedel. Rituximab förefaller vara en bra och effektiv 
behandling när standardbehandling inte är tillräcklig, men man bör vara uppmärksam på 
risken för allvarliga infektioner. 
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